摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Ethyl-1,5-naphthyridin | 90914-89-9

中文名称
——
中文别名
——
英文名称
3-Ethyl-1,5-naphthyridin
英文别名
3-ethyl-[1,5]naphthyridine;1,5-Naphthyridine, 3-ethyl-;3-ethyl-1,5-naphthyridine
3-Ethyl-1,5-naphthyridin化学式
CAS
90914-89-9
化学式
C10H10N2
mdl
——
分子量
158.203
InChiKey
DMNPJJWLTZSSIP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • TRICYCLIC GYRASE INHIBITORS
    申请人:Bensen Daniel
    公开号:US20120238751A1
    公开(公告)日:2012-09-20
    Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.
    本文披露了具有式I结构的化合物,以及作为抗菌有效的三环抑制剂的药用盐、酯和前药,相关的药物组合物、用途和制备该化合物的方法也在考虑之中。
  • [EN] G-A CROSSLINKING CYTOTOXIC AGENTS<br/>[FR] AGENTS CYTOTOXIQUES DE RÉTICULATION G-A
    申请人:FEMTOGENIX LTD
    公开号:WO2020157491A1
    公开(公告)日:2020-08-06
    The invention relates to a compound of formula (I): or salts, solvates, isomers or tautomers thereof, wherein; A is a group selected from: R1 is selected from H and halogen; either R2 is selected from -CH2-halogen, C1-6 alkyl and H, and R3 is H or is absent; or R2 and R3 together with the carbon atoms to which they are attached form a cyclopropyl ring; SP is a spacer group; B is a polycyclic group: R11, R12, R13 and R14 are selected such that either: (aa) one of R11, R12, R13 and R14 is E and another of R11, R12, R13 and R14 is an optionally substituted Ar1 group; or (ab) one of R11, R12, R13 and R14 is Rx, wherein Rx is Ar1-Z1-E or -E1-Z1-Ar1; and Ar1 is an optionally substituted C5-20 aryl or C5-10 heteroaryl groupeach E is independently selected from (CH2)j-S(0)2-NR25R26, (CH2)j-S(0)2-0H, CH2CH2[0CH2CH2]WR25 and E1; and Z1 is NR26, C(=0)-0, O or is absent and these compounds are useful as medicaments, in particular as anti-proliferative agents.
    该发明涉及一种化合物,其化学式为(I):或其盐、溶剂合物、异构体或互变异构体,其中;A是从中选择的一个基团:R1从H和卤素中选择;R2从-CH2-卤素、C1-6烷基和H中选择,R3是H或不存在;或者R2和R3与它们连接的碳原子一起形成环丙基环;SP是一个间隔基团;B是一个多环基团:R11、R12、R13和R14被选择为:(aa) R11、R12、R13和R14中的一个是E,另一个是可选择取代的Ar1基团;或者(ab) R11、R12、R13和R14中的一个是Rx,其中Rx是Ar1-Z1-E或-E1-Z1-Ar1;Ar1是可选择取代的C5-20芳基或C5-10杂环芳基,每个E独立选择自( )j-S(0)2-NR25R26、( )j-S(0)2-0H、 [0 ]WR25和E1;Z1是NR26、C(=0)-0、O或不存在,这些化合物可用作药物,特别是作为抗增殖剂。
  • 10a-Azalide Compound
    申请人:Sugimoto Tomohiro
    公开号:US20090281292A1
    公开(公告)日:2009-11-12
    [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae , erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.
    【目标】提供一种具有新结构的化合物,对流感嗜血杆菌和红霉素耐药菌(例如耐药肺炎球菌和链球菌)以及传统的红霉素敏感菌具有有效作用。 【解决方案】本发明提供了一种新型10a-氮杂环十六元化合物,其化学式为(I),其药学上可接受的盐或其溶剂化物,或其制备的中间体。该化合物对流感嗜血杆菌、红霉素耐药性肺炎球菌等具有卓越的抗菌活性,因此可以作为治疗传染病的药物。
  • BENZOFURO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS)
    申请人:Samsung Display Co., Ltd.
    公开号:EP3693372A1
    公开(公告)日:2020-08-12
    The present invention relates to benzofuro[3',2':4,5]imidazo[1,2-a]pyridinederivatives and related compounds for use in organic light emitting devices (OLEDs). The OLED includes two electrodes and an organic layer disposed between the electrodes including a compound of the present invention. The compounds of the present invention are represented by Formula 1: in Formula 1, A11 is a C1-C60 heterocyclic group, A12 is a C5-C60 carbocyclic group or a C1-C60 heterocyclic group, X11 is O, X12 is C, X13 is selected from N, C, and C(R13), X14 is selected from N, C, and C(R14), and X13 and X14 are linked via a single bond or a double bond.
    本发明涉及用于有机发光器件(OLED)的苯并呋喃并[3',2':4,5]咪唑并[1,2-a]吡啶二衍生物及相关化合物。 OLED 包括两个电极和置于电极之间的有机层,有机层中包括本发明的化合物。 本发明的化合物由式 1 表示: 式 1 中,A11 是 C1-C60 杂环基团,A12 是 C5-C60 碳环基团或 C1-C60 杂环基团,X11 是 O,X12 是 C,X13 选自 N、C 和 C(R13),X14 选自 N、C 和 C(R14),X13 和 X14 通过单键或双键相连。
  • BET bromodomain inhibitors and therapeutic methods using the same
    申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    公开号:US10391175B2
    公开(公告)日:2019-08-27
    Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.
    本研究公开了 BET 基链抑制剂和含有这些抑制剂的组合物。此外,还公开了将 BET 基链抑制剂用于治疗 BET 基链抑制可带来益处的疾病和病症(如癌症)的方法。
查看更多